These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
602 related items for PubMed ID: 11291426
21. Nocturnal growth hormone (GH) secretion is eliminated by infusion of GH-releasing hormone antagonist. Ocampo-Lim B, Guo W, DeMott-Friberg R, Barkan AL, Jaffe CA. J Clin Endocrinol Metab; 1996 Dec; 81(12):4396-9. PubMed ID: 8954048 [Abstract] [Full Text] [Related]
25. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects. Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, Valenti G, Cocchi D, Müller EE, Camanni F. J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330 [Abstract] [Full Text] [Related]
28. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide. Rigamonti AE, Cavallera G, Bonomo S, Deghenghi R, Locatelli V, Cella SG, Müller EE. Eur J Endocrinol; 2001 Nov; 145(5):635-44. PubMed ID: 11720883 [Abstract] [Full Text] [Related]
29. Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli. Jaffe CA, DeMott-Friberg R, Barkan AL. J Clin Invest; 1996 Feb 15; 97(4):934-40. PubMed ID: 8613546 [Abstract] [Full Text] [Related]
30. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. Cordido F, Peñalva A, Dieguez C, Casanueva FF. J Clin Endocrinol Metab; 1993 Apr 15; 76(4):819-23. PubMed ID: 8473389 [Abstract] [Full Text] [Related]
31. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man. Giustina A, Girelli A, Doga M, Bodini C, Bossoni S, Romanelli G, Wehrenberg WB. J Clin Endocrinol Metab; 1990 Sep 15; 71(3):580-4. PubMed ID: 2118535 [Abstract] [Full Text] [Related]
32. Radiation and neuroregulatory control of growth hormone secretion. Ogilvy-Stuart AL, Wallace WH, Shalet SM. Clin Endocrinol (Oxf); 1994 Aug 15; 41(2):163-8. PubMed ID: 7923820 [Abstract] [Full Text] [Related]
33. The GHRH/GHRP-6 test for the diagnosis of GH deficiency in elderly or severely obese men. Haijma SV, van Dam PS, de Vries WR, Maitimu-Smeele I, Dieguez C, Casanueva FF, Koppeschaar HP. Eur J Endocrinol; 2005 Apr 15; 152(4):575-80. PubMed ID: 15817913 [Abstract] [Full Text] [Related]
34. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion. Grottoli S, Procopio M, Maccario M, Zini M, Oleandri SE, Tassone F, Valcavi R, Ghigo E. J Clin Endocrinol Metab; 1997 Jul 15; 82(7):2261-5. PubMed ID: 9215304 [Abstract] [Full Text] [Related]
35. Defective hypothalamic growth hormone (GH)-releasing hormone activity may contribute to declining GH secretion with age in man. degli Uberti EC, Ambrosio MR, Cella SG, Margutti AR, Trasforini G, Rigamonti AE, Petrone E, Müller EE. J Clin Endocrinol Metab; 1997 Sep 15; 82(9):2885-8. PubMed ID: 9284714 [Abstract] [Full Text] [Related]
36. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women. Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M. J Clin Endocrinol Metab; 1993 Feb 15; 76(2):374-7. PubMed ID: 8432781 [Abstract] [Full Text] [Related]
37. Somatostatin pretreatment enhances growth hormone (GH) responsiveness to GH-releasing hormone: a potential new diagnostic approach to GH deficiency. Tzanela M, Guyda H, Van Vliet G, Tannenbaum GS. J Clin Endocrinol Metab; 1996 Jul 15; 81(7):2487-94. PubMed ID: 8675565 [Abstract] [Full Text] [Related]
38. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men. Hulse JA, Rosenthal SM, Cuttler L, Kaplan SL, Grumbach MM. J Clin Endocrinol Metab; 1986 Oct 15; 63(4):872-8. PubMed ID: 3091629 [Abstract] [Full Text] [Related]
39. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging. Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, Imperiale E, Mazza E, Baracchi G, Camanni F. Acta Endocrinol (Copenh); 1990 Aug 15; 123(2):169-73. PubMed ID: 2220258 [Abstract] [Full Text] [Related]
40. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy. Vance ML, Kaiser DL, Martha PM, Furlanetto R, Rivier J, Vale W, Thorner MO. J Clin Endocrinol Metab; 1989 Jan 15; 68(1):22-8. PubMed ID: 2491864 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]